By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax  Antibody phage display

Company News
Amgen (AMGN)'s First Biosimilar Biologics License Application For ABP 501 Submitted To FDA 11/30/2015 6:20:06 AM
European Commission (EC) Approves Amgen (AMGN)'s BLINCYTO (blinatumomab) For The Treatment Of Adults With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Precursor Acute Lymphoblastic Leukemia 11/24/2015 6:12:05 AM
Amgen (AMGN) Announces Repatha Preferred Position On CVS Health Commercial Formularies 11/23/2015 9:51:57 AM
CVS Picks Amgen (AMGN)'s Repatha Over Sanofi (SNY)-Regeneron (REGN)'s Cholesterol Drug 11/23/2015 6:58:25 AM
Amgen (AMGN) Release: European Commission Approves Kyprolis (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma 11/20/2015 6:32:46 AM
Novartis AG (NVS) Takes Another Shot at Amgen (AMGN) with Third Biosimilar Filing 11/18/2015 6:19:04 AM
Third Point's Dan Loeb Talks Up An Amgen (AMGN)-Allergan (AGN) Merger 11/18/2015 6:17:18 AM
Amgen (AMGN) To Present IMLYGIC (Talimogene Laherparepvec) Data At The 2015 International Congress Of The Society For Melanoma Research 11/16/2015 3:57:04 PM
Patients Outraged as Amgen (AMGN) Requires Disclosure of All Medical Information for Drug Assistance 11/16/2015 6:46:44 AM
Why Amgen (AMGN) Should Turn Its Attention to Alnylam (ALNY) 11/13/2015 6:08:37 AM